On July 15, Hong Kong's innovative drug sector experienced a significant uptick during afternoon trading, with Innocare and CSPC Pharma leading gains by surging more than 7%. Other notable performers included Ocumension and BeiGene, both climbing over 6%, while Sino Biopharm advanced more than 3%.
The rally was largely driven by a recent policy announcement from China's National Healthcare Security Administration. On July 10, the authority unveiled a plan for the 2025 adjustments to the national basic medical insurance and commercial health insurance drug directories, emphasizing synchronized updates to foster innovation. This favorable development has injected momentum into the sector, with experts predicting sustained attention on biopharmaceutical stocks like innovative drugs in the second half of the year.
Looking ahead, fund managers Guo Peng and Shan Lin from Yongying Health Fund highlighted in their quarterly report that China's innovative drug evolution is not optional but essential. They noted that domestic innovative drugs are currently on the brink of realizing industry-wide benefits, and only companies with robust technological capabilities and consistent clinical value creation will endure market cycles successfully.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。